These findings highlight the importance of promoter-specific BDNF regulation in mediating the neuroplastic effects of ECS, offering insight into the molecular mechanisms that may underlie the therapeutic effects of ECT in depression. The gene discussed is BDNF; the disease is depressive symptom measurement.